- Home
- LBPH vs CNNE Comparison
LBPH vs CNNE Comparison
Compare LBPH & CNNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LBPH
- CNNE
- Stock Information
- Founded
- LBPH 2020
- CNNE 2014
- Country
- LBPH United States
- CNNE United States
- Employees
- LBPH N/A
- CNNE N/A
- Industry
- LBPH Biotechnology: Pharmaceutical Preparations
- CNNE Restaurants
- Sector
- LBPH Health Care
- CNNE Consumer Discretionary
- Exchange
- LBPH Nasdaq
- CNNE Nasdaq
- Market Cap
- LBPH 1.4B
- CNNE 1.2B
- IPO Year
- LBPH 2021
- CNNE N/A
- Fundamental
- Price
- LBPH $59.81
- CNNE $20.76
- Analyst Decision
- LBPH Buy
- CNNE Buy
- Analyst Count
- LBPH 8
- CNNE 2
- Target Price
- LBPH $52.29
- CNNE $27.00
- AVG Volume (30 Days)
- LBPH 834.8K
- CNNE 349.3K
- Earning Date
- LBPH 11-07-2024
- CNNE 11-12-2024
- Dividend Yield
- LBPH N/A
- CNNE 2.30%
- EPS Growth
- LBPH N/A
- CNNE N/A
- EPS
- LBPH N/A
- CNNE N/A
- Revenue
- LBPH N/A
- CNNE $461,900,000.00
- Revenue This Year
- LBPH N/A
- CNNE N/A
- Revenue Next Year
- LBPH N/A
- CNNE $3.29
- P/E Ratio
- LBPH N/A
- CNNE N/A
- Revenue Growth
- LBPH N/A
- CNNE N/A
- 52 Week Low
- LBPH $3.60
- CNNE $16.94
- 52 Week High
- LBPH $59.95
- CNNE $22.99
- Technical
- Relative Strength Index (RSI)
- LBPH 78.81
- CNNE 59.09
- Support Level
- LBPH $59.47
- CNNE $20.01
- Resistance Level
- LBPH $59.85
- CNNE $22.36
- Average True Range (ATR)
- LBPH 0.20
- CNNE 0.55
- MACD
- LBPH -0.84
- CNNE -0.05
- Stochastic Oscillator
- LBPH 86.36
- CNNE 44.44
About LBPH Longboard Pharmaceuticals Inc.
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.
About CNNE Cannae Holdings Inc.
Cannae Holdings Inc is a holding company that manages and operates a group of companies and investments. The company's reportable segments are Restaurant Group, Dun & Bradstreet, Alight, BKFE, Corporate and Other Affiliate Elimination. Majority of the company's revenue is generated from its Restaurant Group segment which represents the operations of O'Charley's and Ninety Nine Restaurants.